317: VC struggles, drug pricing negotiations,...

Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why is Adam talking to a recruiter?We discuss all that and more on this week’s episode of “The Readout LO ...  Show more

What does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that’s partnered with Novo Nordisk? And has a wanted fugitive been posing as a biotech executive? We discuss all that and more on this week’s episode of “The Re ...  Show more

Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen’s next shot at an Alzheimer’s treatment. - Why companies can’t “muscle their way” i ...  Show more

Earnings are filtering in, and companies are seeing a tale of two very different consumers. The group raising concerns about their customer base, and the names not seeing any slowdown. Plus Novo and Eli Lilly nearing a deal with the White house to lower obesity drug prices. Wh ...

Episode 65: Neal and Toby discuss the increasing buzz around potent weight loss drugs with Pfizer's oral version and Ozempic's anti-addiction side effects. Then, Showtime merges with Paramount+, Max absorbs Discovery+, and Disney+ wants to include Hulu. Are we entering the age of ...  Show more

Pharma stocks breaking out, as President Trump inks a drug pricing deal. What it means for the group, and how the broader health care sector is breathing a sigh of relief. Plus Elon Musk and some bingeing backlash. Why the billionaire is calling for customers to cancel their s ...